Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PledOx for prevention of oxaliplatin-induced peripheral neuropathy in first-line metastatic colorectal cancer
2017-004754-42Phase 3Completed
- Sponsor
- Egetis Therapeutics
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of calmangafodipir in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by Egetis Therapeutics. Primary endpoint: Proportion of patients with moderate or severe chronic CIPN at 9 months. Started Dec 2017; status: completed.
02
Drugs
calmangafodipir
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on 2017-004754-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004754-42.